Showing posts with label Nektar Therapeutics. Show all posts
Showing posts with label Nektar Therapeutics. Show all posts

Sunday, May 26, 2019

IBI Notable Community Discussion: The Best Is Yet To Come

Bioscience stocks commenced the week on a rally with the momentum building stronger toward the weekend. Nektar, Portola, Sesen, and especially Regenxbio are trading northbound.
Packing heavy punches, Sesen Bio is knocking market bears toward an approval. Due to the robust VISTA outcomes, Vicinium will ultimately replace Valstar as the standard of care.
In readying for an upcoming approval of NKTR-181, Nektar formed the new subsidiary Inheris. It'll ensure a robust launch for NKTR-181, the silver bullet for the prescription opioid abuse epidemic.
Special thanks of all Integrated BioSci Investing members who participated in our daily discussion. I'm grateful for your intellectual generosity.
In honoring our troops who sacrificed their lives for our freedom, I'm offering a time-limited 50% discounts to new members. Message me if you wish to get your Memorial Day weekend gift.
You only have to do very few things right in your life so long as you don't do too many things wrong. - Warren Buffett
For the Memorial Day weekend, I'll feature another Integrated BioSci Investing Notable Community Discussion ("NCD"). This series is born out of my quest to continually improve the service for our community. As follow, an NCD fills in the gap for members who are unable to join the daily chat due to work and other obligations. As such, present pertinent highlights that we discussed during the week.
On Tuesday, May 21st, Flamman initiated an excellent discussion. As the market traded lower, the opportunistic investor Flamman - at least that's how I viewed him - prudently picked up shares in some key companies. Some of his purchases included the red hot Sesen Bio (SESN), Nektar Therapeutics(NKTR), and Omeros Corporation (OMER). Of note, I recently published updates on both Sesen and Nektar. You should definitely check out those research if you haven't done so. My trading analytics suggest that the momentum is building in Sesen, Nektar, Omer, and Regenxbio. These stocks have been trading on an uptrend earlier in the week.
Figure 1: Notable IBI stocks (Source: Yahoo Finance)

Monday, December 25, 2017

Integrated BioSci Investing: A Season Greeting From Dr. Tran BioSci


  • We're what we are today due to the support of our community of expert readers, who are physicians, scientists, market leaders, fund managers, analysts, executives, and everyday investors.
  • We're greatly appreciative of your stock tips, advice, wisdom, partnership, and friendship.
  • We're continuing to learn and to grow. Merry Christmas and a Happy Holiday to you all.

We've grown much over the years (especially this year) as we’re blessed with a growing community of expert readers, who we view as teachers, business partners, and friends. Despite that we deliver the analytical research and consulting to you, we also learn significantly from your insight, wisdom, and suggestions in the process. Many of our followers are highly accomplished professionals, including physicians, scientists, professors, hedge fund managers, analysts, and executives, as well as other market leaders. We owe you our gratitude, especially Mr. Jacky Xiao, CEO Abelardo Fraga, Drs. Thomas Valdez and Zach Hartman, as well as many others. Much appreciation for teaching us and growing with us as partners.
Figure 1: Dr. Tran BioSci Logo. (Source: Dr. Tran BioSci of Integrated BioSci Investing).
It has been a blessing, as we've made mostly winning calls that greatly benefitted our community. Nektar Therapeutics (NASDAQ:NKTR) appreciated over 210%, Spectrum Pharmaceuticals (NASDAQ:SPPI) delivers over 170% profits, Kite Pharma (NASDAQ:KITE) procured over 82%, Exelixis (NASDAQ:EXEL) banked in over 50%, just to name a few. Our expert interviewing guests, including Biotech Beast, Decision Analytics, and Terry Chrisomalis made stellar calls that profited our readers substantially. And, we are greatly appreciative of their wisdom.
We’re also thankful for Seeking Alpha, Seeking Alpha editors, Robyn Conti, and Daniel Shvartsman for their ongoing guidance and support. In addition, we wish to send our gratitude to Richard Berger, who had advised us on how to grow our marketplace ("MP"). We recommend that you join his MP, Engineered Income Investing. The former executive is wise and has a strong track record of performance.
Figure 2: Notable BioSci Performers. (Source: Google Finance)
Of note, there are many companies we’re featuring in our MP that are highly likely to appreciate substantially in 2018 and for years to come. If you have yet to sign up with Integrate BioSci Investing, right now is a good time to do so to lock in the legacy price (as we're raising the price soon). And, we're implementing stellar developments. Much excitement to come.
On the behalf of Integrated BioSci Investing, we wish you and your family a Merry Christmas and a Happy Holiday. May this season fill you with joy.
Figure 3: Christmas Greeting. (Source: Christmas WallPaper)
Author Note: We're honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics procured more than 210% profits while Spectrum Pharmaceuticals (SPPI) delivered over 180% gains. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.
Notably, we'll increase prices soon. Subscribe to our Marketplace research now to lock in the legacy price and save money in the future.To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and click on the orange "Follow" button. Besides the exclusives, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by following this link.

Thursday, November 23, 2017

Integrated BioSci Investing: A 2017 Thanksgiving Note


  • Our marketplace is growing to deliver increasing value to subscribers.
  • Spectrum Pharmaceuticals is the top performer. Second comes Nektar Therapeutics. Our portfolio is also powered by many other key winners.
  • Kite Pharma was bought out in the recent months.
  • We wish to send our Happy Thanksgiving to all readers, subscribers, and SA.
  • Subscribe to our marketplace service to receive higher level intelligence, to galvanize your portfolio.

For the past 52-weeks, the Biotechnology Index (NASDAQ:IBB) gained 9.75% while key performers in our Integrated BioSci Investing portfolio posted profits far more robust. Kite Pharma (NASDAQ:KITE), now a subsidiary of Gilead Sciences (NASDAQ:GILD) delivered over 247% returns. Spectrum Pharmaceuticals (NASDAQ:SPPI) appreciated over 361%. Nektar Therapeutics (NASDAQ:NKTR) headed north over 250%. And, Amicus Therapeutics (NASDAQ:FOLD) procured over 51% profits.

Source: Google Finance (Notable Small-Caps BioSci Winners)
In 2013, we joined the ride with Seeking Alpha (and in May 2017, we decided to exclusively focus on our bioscience expertise). Since the commencement of our marketplace service (Integrated BioSci Investing) in the past five months, our overall recommendations to subscribers have been highly profitable (especially with key performers, as mentioned above).

For Thanksgiving 2017, we wish to send our appreciation to all readers (and especially subscribers as well as Seeking Alpha) for your readership, friendship, advice, and business. There are many highly intelligent subscribers, who enjoy the mutual learning. Going forward, we hope to continue to deliver our stellar service to you. Thank you all, and Happy Thanksgiving!

Wednesday, June 14, 2017

Nektar Therapeutics: A Sweet Or Sour Investment?


  • In distancing itself from the failed inhaled-insulin Exubera, Nektar has been enjoying much corporate success.
  • Having two FDA-approved products and its proven technology (licensed to various firms), Nektar is generating meaningful sales.
  • Despite temporarily lowered its earnings, the increased spending on research and development will catapult sales prospects.
  • With 150% share price appreciation in the past five years, valuation metrics indicate that the firm is still a bargain.

After a decade plus of failed investment in the inhaled insulin, Exubera, Pfizer Inc. (NYSE:PFE) cut the loses via terminating its partnership with Nektar Therapeutics (NASDAQ:NKTR) on Oct. 18, 2007. Next year, Nektar gave up the hope for inhaled insulin by terminating all negotiations (with potential marketing partners) for the "the bong."
Notably, Exubera failed due to user inconvenience, and more importantly, the increased incidence of lung cancer found in smokers. As if inhaled insulin is an albatross, MannKind Corporation (NASDAQ:MNKD is also struggling to generate meaningful sales for its FDA-approved inhaled insulin Afrezza (despite the drug's favorable efficacy and safety profiles).
Whether the higher cancer cases in patients who used Exubera is due to insulin or the tobacco's deleterious effects is still up to the jury. Nevertheless, Elam Nevan (the former Vice President of Pfizer Pulmonary Division in charge of the Exubera development) has moved on. The Harvard graduate is now focusing on innovating a once-weekly insulin for AntriBio (OTC:ANTB).
In similar fashion, Nektar has shed off the dead weight of inhaled insulin. For almost a decade, the firm has refocused its efforts to fruitful therapeutic designs.
To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.